A marca ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN, fundada em 2010 (os Estados Unidos de América), a 496 marcas irmãs e 17477 marcas concorrentes. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN es una marca de BRISTOL-MYERS SQUIBB COMPANY, que cotiza en la bolsa de valores de New York. ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN pertence ao setor de negócios Fabricantes de medicamentos.
Preço da ação e lucratividade da ação BRISTOL-MYERS SQUIBB COMPANY (ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)
Compre ações BRISTOL-MYERS SQUIBB COMPANY com
(0% commission and fractional shares)
Seu capital está sujeito a risco. Outras taxas se aplicam. Para mais informações, visite etoro.com/trading/fees.
Simulador de investimento :
Valorização da sua carteira
BRISTOL-MYERS SQUIBB COMPANY
(ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)
ação 5 anos*
USD 40,83
Compartilhe o histórico de preços BRISTOL-MYERS SQUIBB COMPANY (ASIDE: A PHASE IIIB, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ABATACEPT ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY IN)
*dividendos e custo de ordem de Bolsa não incluídos
as performances anteriores não predizem as performances futuras
as performances anteriores não predizem as performances futuras
